What’s Trending?

Novartis touts latest Zolgensma data as SMA competition against Biogen, Roche heats up esagonowsky Fri, 06/18/2021 - 14:33 [...]
Fri, Jun 18, 2021
Source FiercePharma
Key senator calls for Woodcock's removal as FDA fallout from Biogen Alzheimer's approval heats up nhigginsdunn Fri, 06/18/2021 - 11:14 [...]
Fri, Jun 18, 2021
Source FiercePharma
Moderna plots 155 new hires in 2021 amid major mRNA vaccine manufacturing expansion aliu Fri, 06/18/2021 - 11:03 [...]
Fri, Jun 18, 2021
Source FiercePharma
AstraZeneca scores win in EU COVID-19 vaccine lawsuit, saying it can 'substantially exceed' court supply mandate esagonowsky Fri, 06/18/2021 - 09:19 [...]
Fri, Jun 18, 2021
Source FiercePharma
Axial spondyloarthritis affects approximately one in 200 people in the UK [...]
Fri, Jun 18, 2021
Source PharmaTimes
Xeljanz reduced the incidence of death or respiratory failure compared to placebo in hospitalised patients [...]
Fri, Jun 18, 2021
Source PharmaTimes
POLQ inhibitors could be used to kill PARP inhibitor-resistant cancer cells [...]
Fri, Jun 18, 2021
Source PharmaTimes
NHSX and Accelerated Access Collaborative (AAC) have backed 38 AI-driven research projects [...]
Fri, Jun 18, 2021
Source PharmaTimes
AstraZeneca
AstraZeneca today welcomed the ruling by the Court of First Instance in Brussels. The European Commission had requested 120 million vaccine doses cumulatively by the end of June 2021, and a total of 300 million doses by the end of September 2021. The judge ordered delivery of 80.2 million doses [...]
Fri, Jun 18, 2021
Source WorldPharmaNews
CureVac
CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced results of the second interim analysis of its international pivotal Phase 2b/3 study in approximatively 40,000 subjects (the HERALD study) of CureVac's first-generation COVID-19 vaccine candidate, CVnCoV. [...]
Thu, Jun 17, 2021
Source WorldPharmaNews
One of the main reasons for the hold-ups in the mass vaccination campaigns against COVID-19 are the precautions that must be taken regarding the handling of the vaccines and their administration. They have to be transported under very specific conditions and the syringes used for their administration must be prepared [...]
Thu, Jun 17, 2021
Source WorldPharmaNews
Moderna, Inc.
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. government has purchased an additional 200 million doses of Moderna's COVID-19 vaccine, including the option to purchase other COVID-19 vaccine candidates from Moderna's pipeline. [...]
Wed, Jun 16, 2021
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews